Moderna
Search results
Drug Classes. Our goal is clear: we want to provide better medicines for patients worldwide. Our toolbox includes a broad range of drug classes and platform technologies including mRNA-based therapies, cell therapies, small molecules as well as antibodies and other protein-based therapies.
BioNTech SE ( / biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek [2] short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
BioNTech is a fully integrated, global immunotherapy powerhouse. We have been working on automated and digitized processes and build continuously capabilities for specialized manufacturing, either for individualized vaccines or for large-scale products like our COVID-19 vaccine.
Based on our modular multi-platform approach we harness breakthrough technologies across different drug classes and modalities to create tailored treatment approaches for oncology and infectious diseases ushering in a new era of immunotherapies.
May 21, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of...
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Oct 15, 2021 · BioNTech, a German immunotherapy company, had pioneered a new genetic technology that uses a wisp of genetic code from a virus—called messenger RNA—to prompt cells to make antibodies that fight off that virus. 4 For decades, scientists had been working on similar concepts but frequently met defeat because of issues related to the structure ...
Apr 9, 2020 · BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.
BioNTech, a German immunotherapy company, had pioneered a new genetic technology that uses a wisp of genetic code from a virus—called messenger RNA—to prompt cells to make antibodies that fight off that virus 4.
